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U.S.A.) has been shown to prolong overall survival 
(o s ) in previously untreated poor-prognosis patients 
with advanced r c c  3.
2.  THE mTOR PATHWAY
A substantial body of research, including clinical and 
preclinical studies, has identified a central role for the 
mt o r  signalling pathway in cell growth, proliferation, 
survival, and angiogenesis. Aberrations of mt o r -
mediated signalling pathways and mt o r  upregulation 
have been discovered in many different tumour types, 
establishing the mt o r  pathway and its inhibition as a 
promising treatment target in human cancers.
multiple stimuli such as growth factors [for ex-
ample, epidermal growth factor (e g f ), platelet-derived 
growth factor (p d g f ), and insulin-like growth factor 
(i g f )], nutrients, oxygen, and stress can lead to activation 
of the mt o r  pathway and downstream signalling.
The mt o r  kinase, the central regulator of the 
mt o r  signalling pathway, is a sizeable (289 kDa) 
polypeptide serine/threonine–specific kinase that is 
part of the phosphoinositide 3 kinase (p i3k)–related 
kinase family 4. By regulating general protein bio-
synthesis, mt o r  kinase is involved in the control of a 
wide variety of growth-related cellular functions such 
as transcription, translation, membrane trafficking, 
protein degradation, and reorganization of the actin 
cytoskeleton 4,5.
2.1  Upstream Activation of mTOR Signalling
Signalling through the mt o r  pathway starts with the 
receipt of cell growth and survival signals relayed 
to the internal cellular environment by r t k s on the 
plasma membrane. Activation of protein kinase B 
[Akt (a serine/threonine protein kinase)] by p i3k is 
the key event in the signalling cascade. It results from 
an accumulation of phosphatidylinositol (3,4,5)-tris-
phosphate (p i p3) formed by p i3k from phosphati-
dylinositol 4,5-bisphosphate (p i p2), which leads to 
phosphorylation of Akt.
Once substantially accumulated, the phospholipid 
p i p3 serves as a source for recruiting kinases to the 
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1.  INTRODUCTION
Over the last few years, treatment for metastatic 
renal cell carcinoma (mr c c ) has undergone a para-
digm shift from the mainstay of cytokine therapy 
(interferon alfa and interleukin-2) to new targeted 
therapies, including multiple receptor tyrosine kinase 
(r t k ) inhibitors and mammalian target of rapamycin 
(mt o r ) inhibitors. The new r t k  inhibitors, which 
include sunitinib (Sutent: Pfizer Canada, Kirkland, 
QC) and sorafenib (Nexavar: Bayer HealthCare 
AG, Leverkusen, Germany), interfere with tumour-
cell proliferation and angiogenesis. Sunitinib and 
sorafenib have both shown efficacy in patients with 
advanced good- to intermediate-prognosis r c c . Suni-
tinib has demonstrated activity as a first-line therapy 
for mr c c  1, and sorafenib has demonstrated activity 
in patients with failure of prior cytokine therapy 2. 
As compared with interferon alfa, the mt o r  inhibitor 
temsirolimus (CCI-799; Torisel: Wyeth, madison, NJ, KAPOOR
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plasma membrane, including the Akt family of ki-
nases and pyruvate dehydrogenase kinase 1 (p d k 1). 
The p d k 1 activates Akt, partly through phosphoryla-
tion, and Akt subsequently phosphorylates a number 
of downstream targets, including mt o r  kinase, whose 
increasing phosphorylation by Akt further enhances 
protein synthesis. These Akt targets play key roles 
in regulating critical cellular functions including 
proliferation, apoptosis, glucose homeostasis, cell 
size, nutrient response, and d n a  damage 6–8.
In normal tissues, the tumour suppressor gene 
PTEN (phosphatase and tensin homologue deleted 
on chromosome 10) is a negative regulator of the 
Akt pathway, acting by downregulating p i3k hyper-
activity through dephosphorylation of p i p3 to p i p2. In 
many cancers, this PTEN tumour suppressor function 
is not active, allowing p i3k to activate Akt. There is 
substantial evidence that inactivation of PTEN may be 
more important than mutation of p53 in many adult 
epithelial tumours 9. Somatic alteration and mutation 
of PTEN has been shown to be a common event in 
tumours such as melanoma, glioblastoma, prostate 
cancer, and endometrial cancer 10.
The p t e n protein encoded by the PTEN gene is an 
enzyme that facilitates dephosphorylation of p i p3 to 
p i p2. With growth-factor stimulation (i g f, e g f, p d g f), 
p i p3 is upregulated. Elevated p i3k has been linked 
to transformation by oncogenes and to stimulation 
through the p d g f  receptor. The lipid phosphatase 
activity of p t e n and its ability to dephosphorylate 
p i p3 and act as a “countermeasure” for p i3k signalling 
suggests that p t e n functions as a significant tumour 
suppressor by directly antagonizing the activity of 
the p i3k/Akt signalling pathway (Figure 1).
Significant research has now shown the tumour 
suppressor genes tuberous sclerosis 1 (TSC1) and 2 
(TSC2) to be key inhibitors of the mt o r  pathway 5. 
After Akt is stimulated by growth factors and mito-
genic stimuli through the p i3k pathway, the Akt 
complex phosphorylates and subsequently destabi-
lizes the t s c complex (Figure 2). This destabilization 
of the tumor suppressors t s c1 and t s c2 subsequently 
activates mt o r  via a small protein called Rheb (ras 
homolog enriched in brain).
2.2  Dual Pathway Activity: Downstream mTOR 
Signalling Targets
The cell replication process is controlled by mt o r  
through two downstream pathways (Figure 3) 
mediated by two key proteins: 4EBP1 (translation 
initiation factor 4E binding protein 1) and p70S6K1 
(ribosomal p70S6 kinase). When 4EBP1 is activated 
by mt o r , it dissociates from eIF-4E (eukaryotic 
translation factor), and leads to cap-dependent mes-
senger (mr n a) translation. These mr n a  encode for 
c-myc, cyclin D1, ornithine decarboxylase, and 
hypoxia-inducible factor (h i f), leading to upregula-
tion of a number of growth factors, including the 
key angiogenic vascular endothelial growth fac-
tor (v e g f),  p d g f, and transforming growth factor 
(t g f) 11. Synthesis of h i f  is therefore partly regulated 
by mt o r  and normally degraded by the VHL (von 
Hippel–Lindau) gene and its proteins. Dysregula-
tion of the VHL gene, seen in clear-cell renal cell 
carcinomas, results in h i fα overexpression and in 
increased v e g f, p d g f, and t g f. Overexpression of 
h i f  can therefore be controlled by mt o r  inhibition. 
Activation of the p70S6K1 pathway leads to the 
translation of mr n a  that encodes ribosomal pro-
teins, elongation factors, and other proteins that are 
necessary for movement from the G1 phase to the 
S phase of the cell cycle.
Substantial preclinical and clinical data have 
shown the p t e n/p i3k/Akt/mt o r  pathway to be a major 
oncogenic pathway in the development of some of the 
most common cancers and a major therapeutic target 
in the treatment of human malignancy.
f i g u r e  1 The phosphoinositide 3 kinase (p i3k)/protein kinase B 
(Akt) signalling pathway 10. p i p2 = phosphatidylinositol 
(4,5)-bisphosphate; p i p3 = phosphatidylinositol (3,4,5)-tris-
phosphate; p t e n = phosphatase and tensin homolog.
f i g u r e  2 Stimulation of protein kinase B (Akt) by growth 
factors and mitogens in a p i3k (phosphoinositide 3 kinase)–
dependent manner phosphorylates and subsequently destabi-
lizes the tuberous sclerosis (Tsc1/Tsc2) complex. 10 p d k  = 
pyruvate dehydroge  nase kinase; mt O r  = mammalian target 
of rapamycin.mTOR INHIBITION IN KIDNEY CANCER
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3.  INHIBITORS OF mTOR
3.1  Sirolimus
Sirolimus (Rapamune: Wyeth, madison, NJ, U.S.A.), 
initially discovered as an antifungal antibiotic from 
soil on Rapa Nui (formerly called Easter Island), 
was recognized in its early development to have an-
ticancer activity (at high doses in murine models 12) 
and a significant immunosuppressive effect, which 
although detrimental in fighting infections, proved to 
be beneficial in transplantation 13. After its approval 
for transplant immunosuppression in 1999, sirolimus 
was found to have a significant antitumour effect 
in experimental models of r c c . In vitro, sirolimus 
changed murine renal cancer cells from an invasive 
to a noninvasive phenotype, reducing spread and 
metastatic progression. It also reduced cyclin D1 and 
increased p27Kip1, inhibiting G1-to-S transition 14 and 
potentially slowing tumour growth 15.
In several murine models of r c c  tumour progres-
sion, sirolimus was shown to slow tumour growth and 
metastatic progression and to prolong survival, even 
in the presence of pro-oncogenic cyclosporine 14. 
Further studies examining human r c c  pulmonary 
metastases in mice with severe combined immu-
nodeficiency demonstrated the antitumour efficacy 
of sirolimus with significant reduction of the pro-
oncogenic cytokines t g f β and v e g f  16. In contrast 
to cyclosporine (which has been shown to promote 
t g f β), sirolimus has been shown to have an anti-
angiogenic effect through downregulation of v e g f  15 
and potentially a specific effect on tumour vessel 
thrombosis, which may also contribute to its anti-
neoplastic action through an indirect mechanism 17. 
Blockade of mt o r  has an inhibitory effect on activity 
by upstream molecules such as Akt, which occur in 
some cancers (for example, Kaposi sarcoma) because 
of loss of regulation by the tumor suppressor p t e n  9.
3.2  Everolimus
Everolimus (RAD001: Novartis Pharmaceuticals, 
St. Louis, mO, U.S.A.) an oral mt o r  inhibitor, has 
been shown to have both immunosuppressant and 
anti-neoplastic properties. At the 2006 annual meet-
ing of the American Society for Clinical Oncology 
(a s c o ), Amato and colleagues presented a phase ii 
trial in patients with r c c  treated with everolimus 
after cytokine or cytotoxic therapy. In that study, 25 
patients receiving a daily dose of 10 mg showed a 
median progression-free survival (p f s) of more than 
9 months 18. In phase i and ii trials, the most common 
adverse events with everolimus were rash (46%), 
stomatitis or mucositis (40%), fatigue (32%), and 
nausea (25%). The most common laboratory abnor-
malities were anemia (9%), hypercholesterolemia 
(9%), hyperglycemia (8%), thrombocytopenia (7%), 
hypertriglyceridemia (3%), and leucopenia or neu-
tropenia (2%).
These phase i and phase ii data in patients with 
advanced r c c  identified significant activity that led 
to a subsequent larger phase iii second-line trial. In 
that trial 19, everolimus delayed disease progression 
in mr c c  patients who had progressed on previous 
targeted therapy (sorafenib, sunitinib). The 410 study 
patients were randomized 2:1 (everolimus:placebo). 
The primary endpoint was p f s, with 290 events re-
quired to achieve 90% power. Secondary endpoints 
were safety, response, patient-reported outcomes, and 
o s . Key eligibility criteria were mr c c  with clear-cell 
component, measurable disease, and progressive 
disease at or within 6 months of treatment with 
sunitinib, sorafenib, or both. (Prior bevacizumab and 
cytokine treatment were also permitted.) Crossover 
was allowed in the study, meaning that patients who 
progressed on therapy were unblinded and allowed 
to receive everolimus if they had been randomized 
to placebo.
Of the 410 patients randomized, 272 received 
everolimus 10 mg daily, and 138 received placebo. 
median age was 61 years in the treatment group and 
60 years in the placebo group. main sites of metastasis 
were lung (73%, 81%), bone (37%, 31%), and liver 
(35%, 36%). more than 90% of the patients in both 
arms had more than one site of metastatic disease. 
Patients with prior nephrectomy constituted 96% 
of the everolimus arm and 95% of the placebo arm, 
and were otherwise comparable. In the everolimus 
arm, 46% of patients had been treated with sunitinib, 
28% with sorafenib, and 28% with both agents. 
Patient discontinuation in the everolimus arm was 
31% because of progressive disease, 10% because 
of adverse events, and 3% because of death. In the 
placebo arm, 73% patients discontinued because of 
progressive disease, 1% because of adverse events, 
and 2% because of death.
Interim analysis showed that median p f s was 
4 months in the everolimus arm and 1.9 months in 
f i g u r e  3 Control of the cell replication process by mammalian 
target of rapamycin (mt O r ) through two downstream path-
ways 10. 4EBP1/eIF-4E = eukaryotic translation initiation 
factor 4E binding protein 1 / eukaryotic translation fac  tor; 
p70S6K = ribosomal p70S6 kinase.KAPOOR
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the control arm, a statistically significant difference 
(p < 0.001). Because of crossover, 80% patients on 
placebo switched to everolimus, and so o s  did not 
show a significant difference.
Inhibition of mt o r  with everolimus was fairly 
well tolerated. Common side effects were mouth ul-
cers or stomatitis (40% vs. 8% placebo), asthenia or 
fatigue (28% vs. 24%), rash (25% vs. 4%), diarrhea 
(17% vs. 3%), anorexia (16% vs. 6%), nausea (15% 
vs. 8%), vomiting (12% vs. 4%), cough (12% vs. 4%), 
peripheral edema (10% vs. 3%), pneumonitis (8% 
vs. 0%), and dyspnea (8% vs. 2%). main laboratory 
abnormalities (all grades) included anemia (91% vs. 
76%), lymphopenia (42% vs. 29%), thrombocytope-
nia (20% vs. 2%), and neutropenia (11% vs. 3%). 
Hypercholesterolemia, hypertriglyceridemia, and 
hyperglycemia were higher in the everolimus arm 
than in the placebo arm, as was expected, given the 
mt o r -inhibitor class of the drug.
Based on these data showing statistically signifi-
cant improvement in p f s as compared with placebo, 
everolimus established clinical benefit as a second-
line therapy in patients who progress on first-line 
targeted therapy, including sunitinib and sorafenib. 
Everolimus can be proposed as the new standard of 
care in the second-line setting for patients progressing 
on targeted therapy with v e g f  inhibitor.
3.3  Temsirolimus
Temsirolimus, a soluble ester analog of rapamycin, 
was selected for development as an anticancer agent 
based on its prominent antitumour profile and favour-
able pharmacologic and toxicologic characteristics in 
preclinical studies 20. Compared with rapamycin, temsi-
rolimus was found to have improved aqueous solubility, 
bioavailability, and stability as an anticancer agent 21.
Temsirolimus is a specific inhibitor of mt o r  ki-
nase 22 that binds to an intracellular protein, Fkbp12, 
which in turn forms a complex that inhibits the mt o r  
pathway 23. By inhibiting mt o r  signalling, temsirolimus 
inhibits the translation of mr n a  that encodes proteins 
required for G1 progression and S-phase initiation, and 
that mediate cell growth and angiogenesis 24. In phase i 
studies, antitumour activity in a number of cancer types 
was observed over a broad dose range (Table i).
Although mutations in PTEN have not been de-
tected, PTEN gene expression is often downregulated 
in r c c  29. A phase ii single-agent study was con-
ducted to evaluate the efficacy, safety, and pharma-
cokinetics of CCI-779 in patients with advanced 
refractory r c c . This randomized double-blind mul-
ticentre trial in 111 patients with cytokine-refractory 
mr c c  included patients with poor-risk features. Pa-
tients were randomly assigned to receive 25 mg, 
75 mg, or 250 mg CCI-779 weekly as a 30-minute 
intravenous (IV) infusion. Patients were evaluated 
for tumour response, time to tumour progression (t t p), 
survival, and adverse events. The CCI-779 produced 
an objective response rate of 7% (1 complete response 
and 7 partial responses) and minor responses in 26% 
of the study patients. median t t p was 5.8 months, 
and median survival was 15.0 months (Figure 4). 
Within each risk group, the median survivals of 
patients at each dose level were similar.
The most frequently occurring adverse events of 
all grades related to CCI-779 were maculopapular rash 
(76%), mucositis (70%), asthenia (50%), and nausea 
(43%). Reasons for dose reductions included throm-
bocytopenia (20%), mucositis (16%), hypertriglyceri-
demia (5%), and neutropenia (1%). In 19% of patients, 
treatment was discontinued because of drug-related 
adverse events. maculopapular rash (5 patients) was 
the most frequent reason for treatment discontinua-
tion. Pneumonitis was seen in 6 patients, with 2 being 
withdrawn from study, 2 worsening after drug restart, 
and 2 having no recurrence of pneumonitis after drug 
restart. Retrospectively, 49 patients were categorized 
as being poor-prognosis patients. The CCI-779–treated 
patients in this poor-risk group experienced a median 
o s  that was longer by a factor of 1.7 than that expe-
rienced by the first-line interferon-treated poor-risk 
group reported by motzer et al. 30 (Table ii).
In a phase i study, the maximal tolerated dose 
of a combination of temsirolimus with interferon in 
advanced r c c  patients was temsirolimus 15 mg IV 
once weekly with interferon 6×106 IU subcutaneously 
3 times weekly 31. The significant activity noted in 
patients with poor-prognosis features led to a major 
phase iii trial in advanced r c c patients with poor 
prognostic features. Patients with advanced r c c  and 
no prior systemic therapy were enrolled in the open-
label study if they had at least 3 of the following 6 
mekhail poor-prognosis risk factors:
f i g u r e  4 Median time to tumour progression in patients 
randomly assigned to receive 25 mg, 75 mg, or 250 mg of 
CCI-779 (temsirolimus) weekly 29.mTOR INHIBITION IN KIDNEY CANCER
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Lactate dehydrogenase level greater than 1.5 times  • 
the upper limit of normal
Hemoglobin below the lower limit of normal • 
Corrected calcium greater than 10 mg/dL • 
Time from diagnosis to first treatment under  • 
1 year
Karnofsky performance status 60–70 • 
Disease metastatic to multiple organs • 
At 209 sites in 26 countries, 626 patients were 
enrolled, of whom 67% had undergone prior nephre-
ctomy. That proportion of patients with nephrectomy 
was much lower than the more than 90% of patients 
with prior nephrectomy in the sunitinib and sorafenib 
registration trials, likely because the temsirolimus–
interferon patients had a poor prognosis and may not 
have been able to tolerate surgical intervention.
Patients were randomized (1:1:1) to one of 3 arms:
interferon up to 18 •  ×106 IU subcutaneously 
3 times weekly (arm 1),
temsirolimus 25 mg IV once weekly (arm 2), or • 
temsirolimus 15 mg IV once weekly with inter- • 
feron 6×106 IU subcutaneously 3 times weekly 
(arm 3).
The primary study endpoint was o s , and the study 
was powered to compare the temsirolimus arms with 
the interferon-only arm.
The three most frequently occurring adverse 
events were asthenia (27% in arm 1, 12% in arm 2, 
30% in arm 3), anemia (24%, 21%, 39%), and dyspnea 
(8%, 9%, 11%). Less-common adverse events in-
cluded nausea (5%, 4%, 2%), vomiting (0%, 1%, 5%), 
hyperlipidemia (1%, 7%, 2%), hyperglycemia (1%, 
10%, 4%), thrombocytopenia (0%, 1%, 9%), and neu-
tropenia (8%, 3%, 14%). The proportion of patients 
with any grade 3 or 4 adverse event was 85% in arm 1, 
69% in arm 2, and 87% in arm 2, with the difference 
between temsirolimus and interferon and between 
temsirolimus and temsirolimus–interferon being sta-
tistically significant (p ≤ 0.001). more patients in the 
interferon groups discontinued treatment because of 
adverse events (14, 7, and 22 patients respectively).
As compared with interferon alfa (n = 207), 
single-agent temsirolimus (n = 209) was observed to 
significantly increase o s  (10.9 months vs. 7.3 months, 
p = 0.0069) in patients with mr c c  judged to be poor-
risk. By treatment arm, o s  was 7.3 months (inter-
feron), 10.9 months (temsirolimus), and 8.4 months 
(temsirolimus–interferon). median p f s (Figure 5) was 
1.9 months, 3.7 months, and 3.7 months, and objective 
response (complete and partial responses together) was 
7%, 9%, and 11% respectively. The conclusion from 
the study was that, compared with interferon, single-
agent temsirolimus (25 mg IV weekly) significantly 
increases o s , with an acceptable safety profile, in first-
line poor-risk advanced r c c  patients 3. This study was 
the first to show a statistically significant benefit in o s  
as well as in p f s with targeted therapy in mr c c  patients 
with poor-prognosis features. It led to approvals by 
Health Canada and the U.S. Food and Drug Admin-
istration of temsirolimus for the first-line treatment of 
poor-prognosis patients with advanced r c c .
4.  CONCLUSIONS
The importance of mt o r  as a novel target in the 
treatment of advanced r c c  has been demonstrated in 
phase iii clinical trials, both for first-line and second-
line treatment after failure of v e g f r -r t k  inhibitors. 
The mt o r  inhibitors temsirolimus and everolimus 
are well tolerated by patients with advanced r c c . The 
mt o r  inhibitors continue to be investigated as single 
agents and in combination with other anti-neoplastic 
agents such as r t k  inhibitors and v e g f  inhibitors in 
r c c  and other malignancies.
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